Shares of Simulations Plus, Inc. (NASDAQ:SLP) have earned an average broker rating score of 2.00 (Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation.
Analysts have set a 12-month consensus price objective of $25.00 for the company and are anticipating that the company will post $0.14 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Simulations Plus an industry rank of 170 out of 256 based on the ratings given to its competitors.
Several equities research analysts have issued reports on SLP shares. BidaskClub upgraded shares of Simulations Plus from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 25th. Zacks Investment Research upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 20th. Finally, ValuEngine upgraded shares of Simulations Plus from a “buy” rating to a “strong-buy” rating in a research report on Tuesday.
In other news, insider Walter S. Woltosz sold 18,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $20.64, for a total value of $381,840.00. Following the completion of the sale, the insider now directly owns 5,214,539 shares in the company, valued at approximately $107,628,084.96. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David L. Ralph sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $22.74, for a total transaction of $68,220.00. Following the completion of the sale, the director now owns 18,006 shares of the company’s stock, valued at $409,456.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,500 shares of company stock valued at $1,333,990. 31.57% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Advisor Group Inc. lifted its holdings in shares of Simulations Plus by 156.9% in the 4th quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock worth $42,000 after acquiring an additional 1,290 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Simulations Plus by 59,875.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,399 shares of the technology company’s stock worth $51,000 after acquiring an additional 2,395 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in shares of Simulations Plus in the 4th quarter worth approximately $79,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Simulations Plus in the 4th quarter worth approximately $85,000. Finally, MetLife Investment Advisors LLC bought a new stake in shares of Simulations Plus in the 4th quarter worth approximately $108,000. Hedge funds and other institutional investors own 41.28% of the company’s stock.
Shares of SLP stock traded down $0.14 during trading hours on Thursday, reaching $26.94. The stock had a trading volume of 35,586 shares, compared to its average volume of 49,269. Simulations Plus has a 12 month low of $16.70 and a 12 month high of $27.33. The firm has a market capitalization of $460.48 million, a P/E ratio of 53.88 and a beta of -0.52.
Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Tuesday, April 9th. The technology company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. Simulations Plus had a net margin of 23.61% and a return on equity of 22.87%. The company had revenue of $8.47 million during the quarter, compared to analyst estimates of $8.10 million. Analysts anticipate that Simulations Plus will post 0.44 EPS for the current fiscal year.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Article: What are convertible shares?
Get a free copy of the Zacks research report on Simulations Plus (SLP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.